Full clinical trial not needed for Parkinson’s drug patent, IP Australia says

Healthcare 2022-05-24 12:32 pm By Sam Matthews | Melbourne

Please login to bookmark

An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au